[A20-10] Siponimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V

Last updated 20.08.2020

Project no.:
A20-10

Commission:
Commission awarded on 05.02.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Head and nerves

Indication/Intervention:

Adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity

Result of dossier assessment:

Added benefit neither proven for patients with superimposed relapses nor for patients without superimposed relapses.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Project no. Title Status
A20-51 Siponimod (multiple sclerosis) - Addendum to Commission A20-10 Commission completed

Federal Joint Committee (G-BA)

2020-08-20: A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.